1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSpinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) is sponsored by Dept. of the Army -- USAMRAA. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar Spinal Cord Injury Research Program Clinical Translation Research Award Defense Health Agency Contracting Activity - DHACA Document Type:Grants Notice Funding Opportunity Number:HT942524SCIRPCTRA Funding Opportunity Title:Spinal Cord Injury Research Program Clinical Translation Research Award Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Grant Category of Funding Activity:Science and Technology and other Research and Development Expected Number of Awards:2 Assistance Listings:12.
420 -- Military Medical Research and Development Cost Sharing or Matching Requirement:No Last Updated Date:Mar 25, 2024 Original Closing Date for Applications:Aug 30, 2024 Current Closing Date for Applications:Aug 30, 2024 Archive Date:Sep 29, 2024 Estimated Total Program Funding:$ 4,160,000 Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: ## Additional Information Agency Name:Defense Health Agency Contracting Activity - DHACA Description:The SCIRP CTRA is intended to support high-impact and/or new/emerging clinical research that may not be ready for a larger-scale clinical trial and for which feasibility/pilot/optimization studies are necessary.
Projects should demonstrate potential to impact the standard of care, both immediate and long term, or contribute to evidence-based guidelines for the evaluation and care of military Service Members, Veterans, and other individuals living with SCI. Link to Additional Information:[](https://www. grants.
gov/search-results-detail/353186) Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.
Unsaved changes will be lost.
According to the current listing, eligibility includes: This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Confirm the full requirements in the official notice before applying.
Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) is funded by Dept. of the Army -- USAMRAA. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
DoW Duchenne Muscular Dystrophy, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article